Multi-pathway cellular analysis of compound selectivity

Molecular BioSystems

Volumn 6, Issue 10, 2010, Pages 1834-1843

  Hancock, Michael K ^a   Lebakken, Connie S ^a   Wang, Jun ^a   Bi, Kun ^a  

^a INVITROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; PROTEIN KINASE;

ARTICLE; CELL LINE; ENZYME SPECIFICITY; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

BETA-LACTAMASES; CELL LINE; HUMANS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 77956535304     PISSN: 1742206X     EISSN: 17422051     Source Type: Journal    
DOI: 10.1039/c003669b     Document Type: Article

References (37)

1. M. W. Karaman S. Herrgard D. K. Treiber P. Gallant C. E. Atteridge B. T. Campbell K. W. Chan P. Ciceri M. I. Davis P. T. Edeen R. Faraoni M. Floyd J. P. Hunt D. J. Lockhart Z. V. Milanov M. J. Morrison G. Pallares H. K. Patel S. Pritchard L. M. Wodicka P. P. Zarrinkar A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008 26 1 127 32
2. J. Bain L. Plater M. Elliott N. Shpiro C. J. Hastie H. McLauchlan I. Klevernic J. S. Arthur D. R. Alessi P. Cohen The selectivity of protein kinase inhibitors: a further update Biochem. J. 2007 408 3 297 315
3. K. Vogel Z. Zhong K. Bi B. Pollok Developing assays for drug discovery-where have the advances come from Expert Opin. Drug Discovery 2008 3 1 115 125
4. J. M. Wilkinson T. Machleidt V. M. Echeverria K. Vandenheuvel-Kramer J. Honer Z. Zhong K. Bi HTS assays using a disease-relevant cell model for interrogating the MAP kinase pathway initiated by multiple receptors Assay Drug Dev. Technol. 2008 6 3 351 9
5. M. B. Robers T. M C. B. Carlson K. Bi Cellular LanthaScreen and beta-Lactamase Reporter Assays for High-Throughput Screening of JAK2 Inhibitors Assay Drug Dev. Technol. 2008 6 4 519 29
6. G. Zlokarnik P. A. Negulescu T. E. Knapp L. Mere N. Burres L. Feng M. Whitney K. Roemer R. Y. Tsien Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter Science 1998 279 5347 84 8
7. P. A. Marks R. Breslow Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 2007 25 1 84 90
8. R. Roskoski Jr Src kinase regulation by phosphorylation and dephosphorylation Biochem. Biophys. Res. Commun. 2005 331 1 1 14
9. G. Mancuso A. Midiri C. Beninati G. Piraino A. Valenti G. Nicocia D. Teti J. Cook G. Teti Mitogen-activated protein kinases and NF-kappa B are involved in TNF-alpha responses to group B streptococci J. Immunol. 2002 169 3 1401 9
10. L. Shi Z. Zhang S. Fang J. Xu J. Liu J. Shen F. Fang L. Luo Z. Yin Heat shock protein 90 (Hsp90) regulates the stability of transforming growth factor beta-activated kinase 1 (TAK1) in interleukin-1beta-induced cell signaling Mol. Immunol. 2009 46 4 541 50
11. N. Pore Z. Jiang A. Gupta G. Cerniglia G. D. Kao A. Maity EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms Cancer Res. 2006 66 6 3197 204
12. A. S. Ali S. Ali B. F. El-Rayes P. A. Philip F. H. Sarkar Exploitation of protein kinase C: a useful target for cancer therapy Cancer Treat. Rev. 2009 35 1 1 8
13. J. S. Sawyer B. D. Anderson D. W. Beight R. M. Campbell M. L. Jones D. K. Herron J. W. Lampe J. R. McCowan W. T. McMillen N. Mort S. Parsons E. C. Smith M. Vieth L. C. Weir L. Yan F. Zhang J. M. Yingling Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain J. Med. Chem. 2003 46 19 3953 6
14. Y. Kuma G. Sabio J. Bain N. Shpiro R. Marquez A. Cuenda BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo J. Biol. Chem. 2005 280 20 19472 9
15. J. S. Isaacs Y. J. Jung E. G. Mimnaugh A. Martinez F. Cuttitta L. M. Neckers Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway J. Biol. Chem. 2002 277 33 29936 44
16. K. H. Wrighton X. Lin X. H. Feng Critical regulation of TGFbeta signaling by Hsp90 Proc. Natl. Acad. Sci. U. S. A. 2008 105 27 9244 9
17. M. Dokmanovic C. Clarke P. A. Marks Histone deacetylase inhibitors: overview and perspectives Mol. Cancer Res. 2007 5 10 981 9
18. N. Tsuyama I. Danjoh K. Otsuyama M. Obata H. Tahara T. Ohta H. Ishikawa IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3 Biochem. Biophys. Res. Commun. 2005 337 1 201 8
19. J. Vlasakova Z. Novakova L. Rossmeislova M. Kahle P. Hozak Z. Hodny Histone deacetylase inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia protein Blood 2007 109 4 1373 80
20. I. Nusinzon C. M. Horvath Unexpected roles for deacetylation in interferon- and cytokine-induced transcription J. Interferon Cytokine Res. 2005 25 12 745 8
21. Z. A. Knight K. M. Shokat Features of selective kinase inhibitors Chem. Biol. 2005 12 6 621 37
22. M. J. Gray J. Zhang L. M. Ellis G. L. Semenza D. B. Evans S. S. Watowich G. E. Gallick HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas Oncogene 2005 24 19 3110 20
23. T. H. Leu M. C. Maa Functional implication of the interaction between EGF receptor and c-Src Front. Biosci. 2003 8 s28 38
24. C. van Vliet P. E. Bukczynska M. A. Puryer C. M. Sadek B. J. Shields M. L. Tremblay T. Tiganis Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase Nat. Immunol. 2005 6 3 253 60
25. A. S. Tsao D. He B. Saigal S. Liu J. J. Lee S. Bakkannagari N. G. Ordonez W. K. Hong I. Wistuba F. M. Johnson Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion Mol. Cancer Ther. 2007 6 1962 72
26. M. Sato K. Kawai-Kowase H. Sato Y. Oyama H. Kanai Y. Ohyama T. Suga T. Maeno Y. Aoki J. Tamura H. Sakamoto R. Nagai M. Kurabayashi c-Src and hydrogen peroxide mediate transforming growth factor-beta1-induced smooth muscle cell-gene expression in 10T1/2 cells Arterioscler., Thromb., Vasc. Biol. 2004 25 2 341 7
27. Z. W. Li H. Chen R. A. Campbell B. Bonavida J. R. Berenson NF-kappaB in the pathogenesis and treatment of multiple myeloma Curr. Opin. Hematol. 2008 15 4 391 9
28. S. Faivre G. Demetri W. Sargent E. Raymond Molecular basis for sunitinib efficacy and future clinical development Nat. Rev. Drug Discovery 2007 6 9 734 45
29. J. E. Thompson R. M. Cubbon R. T. Cummings L. S. Wicker R. Frankshun B. R. Cunningham P. M. Cameron P. T. Meinke N. Liverton Y. Weng J. A. DeMartino Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor Bioorg. Med. Chem. Lett. 2002 12 8 1219 23
30. L. Adnane P. A. Trail I. Taylor S. M. Wilhelm Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature Methods Enzymol. 2006 407 597 612
31. K. G. Kumar J. Liu Y. Li D. Yu A. Thomas-Tikhonenko M. Herlyn S. Y. Fuchs Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells Cancer Biol. Ther. 2007 6 9 1437 41
32. V. Lacronique A. Boureux V. D. Valle H. Poirel C. T. Quang M. Mauchauffe C. Berthou M. Lessard R. Berger J. Ghysdael O. A. Bernard A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia Science 1997 278 1309 1312
33. R. L. Levine M. Wadleigh J. Cools B. L. Ebert G. Wernig B. J. Huntly T. J. Boggon I. Wlodarska J. J. Clark S. Moore J. Adelsperger S. Koo J. C. Lee S. Gabriel T. Mercher A. D'Andrea S. Frohling K. Dohner P. Marynen P. Vandenberghe R. A. Mesa A. Tefferi J. D. Griffin M. J. Eck W. R. Sellers M. Meyerson T. R. Golub S. J. Lee D. G. Gilliland Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 2005 7 387 397
34. M. Campillos M. Kuhn A. C. Gavin L. J. Bork P. Bork Drug target identification using side-effect similarity Science 2008 321 5886 263 6
35. J. Lamb E. D. Crawford D. Peck J. W. Modell I. C. Blat M. J. Wrobel J. Lerner J. P. Brunet A. Subramanian K. N. Ross M. Reich H. Hieronymus G. Wei S. A. Armstrong S. J. Haggarty P. A. Clemons R. Wei S. A. Carr E. S. Lander T. R. Golub The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science 2006 313 5795 1929 35
36. F. Sams-Dodd Target-based drug discovery: is something wrong? Drug Discovery Today 2005 10 2 139 47
37. S. Jones X. Zhang D. W. Parsons J. C. Lin R. J. Leary P. Angenendt P. Mankoo H. Carter H. Kamiyama A. Jimeno S. M. Hong B. Fu M. T. Lin E. S. Calhoun M. Kamiyama K. Walter T. Nikolskaya Y. Nikolsky J. Hartigan D. R. Smith M. Hidalgo S. D. Leach A. P. Klein E. M. Jaffee M. Goggins A. Maitra C. Iacobuzio-Donahue J. R. Eshleman S. E. Kern R. H. Hruban R. Karchin N. Papadopoulos G. Parmigiani B. Vogelstein V. E. Velculescu K. W. Kinzler Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 2008 321 5897 1801 6